| Literature DB >> 30674329 |
Angela J Toepp1,2, Glória R G Monteiro3, José F V Coutinho3, Adam Leal Lima1,2, Mandy Larson1,2, Geneva Wilson1,2, Tara Grinnage-Pulley1,2, Carolyne Bennett1,2, Kurayi Mahachi1,2, Bryan Anderson1,2, Marie V Ozanne4, Michael Anderson1,2, Hailie Fowler1,5, Molly Parrish1,2, Kelsey Willardson1,2, Jill Saucier6, Phyllis Tyrell6, Zachary Palmer7, Jesse Buch6, Ramaswamy Chandrashekar6, Grant D Brown4, Jacob J Oleson4, Selma M B Jeronimo3, Christine A Petersen8,9,10.
Abstract
BACKGROUND: Visceral leishmaniasis (VL) is a vector borne zoonotic disease endemic in humans and dogs in Brazil. Due to the increased risk of human infection secondary to the presence of infected dogs, public health measures in Brazil mandate testing and culling of infected dogs. Despite this important relationship between human and canine infection, little is known about what makes the dog reservoir progress to clinical illness, significantly tied to infectiousness to sand flies. Dogs in endemic areas of Brazil are exposed to many tick-borne pathogens, which are likely to alter the immune environment and thus control of L. infantum.Entities:
Keywords: Canine leishmaniosis; Progression; Risk-factor; Tick-borne diseases
Mesh:
Year: 2019 PMID: 30674329 PMCID: PMC6345068 DOI: 10.1186/s13071-019-3312-3
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Demographics of Brazil cross-sectional study cohort
| Variable | Value, |
|---|---|
| Sex, | 115 (51.57) |
| Age, mean ± SD (range) (years) | 2.48 ± 2.16 (0.25–13.00) |
| Breed, | 188 (90.38) |
| Appearance | |
| Onychogryphosis | 40 (17.94) |
| Cachexia | 19 (8.52) |
| Wounds/skin lesions | 18 (8.07) |
| Apathy | 4 (1.79) |
| None | 171 (76.68) |
| Tick serology | |
| | 91 (40.81) |
| | 1 (0.45) |
| | 73 (32.74) |
| None | 58 (26.01) |
| Seropositive: three tests | |
| DPP®CVL, SLA, rk39 | 12 (5.38) |
| Seropositive: two tests | |
| DPP®CVL and SLA | 17 (7.62) |
| DPP®CVL and rk39 | 19 (8.52) |
| Seropositive: one test | |
| DPP®CVL | 108 (48.43) |
| SLA | 19 (8.52) |
| rk39 | 22 (9.87) |
| Seronegative (all tests) | 111 (49.78) |
Abbreviation: SD standard deviation
Fig. 1Distribution of Leishmania and tick-borne diseases in Brazilian dogs. a Distribution of tick-borne diseases and Leishmania seropositivity in full cross-sectional study cohort. Overall 82.96% of dogs were seropositive for one or more vector borne disease. b Tick-borne disease serostatus of dogs that tested positive via either ELISA and/or DPP® CVL for Leishmania. c Tick-borne disease serostatus of dogs that were negative via ELISA and DPP® CVL for Leishmania spp.
Univariate analysis of study cohort variables based on Leishmania serostatus. Pearson’s chi-square test and ANOVA were used to analyze categorical variables where appropriate
| Variable | |||
|---|---|---|---|
| Sex, | 54 (24.2) | 61 (27.6) | 0.6886 |
| Age, mean ± SD (range) (years) | 2.45 ± 1.81 (0.42–8.00) | 2.50 ± 2.45 (0.25–13.0) | |
| Breed, | 11 (5.29) | 9 (4.33) | 0.6392 |
| Appearance, | |||
| Onychogryphosis | 21 (19.4) | 19 (16.5) | 0.3691 |
| Cachexia | 8 (7.41) | 11 (9.57) | |
| Physical wounds | 9 (8.33) | 9 (7.83) | |
| Apathy | 0 (0) | 4 (3.48) | |
| None | 81 (75) | 90 (78.3) | |
| Tick disease exposure, | |||
| | 88 (81.5) | 76 (66.1) | 0.0290 |
| | 39 (36.1) | 35 (30.4) | |
| | 39 (36.1) | 34 (29.6) | |
| None | 20 (18.5) | 38 (33.0) | |
Notes: Age differences assessed via Mann-Whitney test. Leishmania+ are dogs that tested positive via the DPP®CVL assay. Leishmania- are dogs that tested negative via the DPP®CVL assay
Abbreviation: SD standard deviation
Dogs seropositive for a tick-borne disease are more likely to be seropositive for Leishmania. Parameter estimates were determined using logistic regression
| Variable | ARR | 95% CI | |
|---|---|---|---|
| (i) Leish serology 1 test | |||
| Sex | |||
| Male | 0.97 | 0.74–1.28 | 0.85 |
| Age | 0.97 | 0.91–1.04 | 0.38 |
| Appearance | |||
| Onychogryphosis | 1.22 | 0.84–1.76 | 0.29 |
| Cachexia | 0.99 | 0.54–1.80 | 0.97 |
| Physical wounds | 1.11 | 0.71–1.74 | 0.63 |
| Apathy | 0.35 | 0.60–2.05 | 0.24 |
| Tick disease serostatus | |||
| positive for 1 | 1.60 | 1.04–2.45 |
|
| positive for 2 | 1.68 | 1.09–2.61 |
|
| positive for 1 | 0.95 | 0.70–1.29 | 0.73 |
| Breed | |||
| Mixed | 0.99 | 0.63–1.54 | 0.95 |
| (ii) Leish serology 2 tests | |||
| Sex | |||
| Male | 0.56 | 0.26–1.20 | 0.14 |
| Tick disease serostatus | |||
| positive for 1 | 4.86 | 1.16–20.3 |
|
| positive for 2 | 2.75 | 0.60–12.7 | 0.19 |
| positive for 1 | 1.76 | 0.77–4.05 | 0.18 |
aBold indicates statistically significant variables
Notes: Leishmaniosis 1 test: Leishmania-positive are dogs that tested positive via DPP®CVL assay or ELISA. Leishmania-negative are dogs that tested negative via the DPP®CVL assay and ELISA. Predictor variables for this model included age, sex, appearance, tick disease status, and breed. Leishmaniosis 2 tests: Leishmania-positive are dogs that tested positive via the DPP®CVL assay and ELISA. Leishmania-negative are dogs that tested negative via the DPP®CVL assay and ELISA. Predictor variables for this model included sex and tick disease serostatus
Abbreviations: CI confidence interval, ARR adjusted relative risk
Demographics of longitudinal study cohort. Combined IDEXX SNAP® 4DX® test results for antibody against Ehrlichia ewingii and Ehrlichia canis, Anaplasma phagocytophilum and Anaplasma platys, Borrelia burgdorferi, and antigen to Dirofilaria immitis
| Variable | IDEXX SNAP® 4DX® + (exposed) | IDEXX SNAP® 4DX® - (unexposed) |
|---|---|---|
| No. | 62 | 149 |
| Age, % ≤ 6 years-old | 79.03 | 88.51 |
| Sex, % male | 50.00 | 51.68 |
Univariate analysis of factors leading to CanL from longitudinal study
| Variable | Leish+ | Leish- | RR | |
|---|---|---|---|---|
| Age, % ≤ 6 years old | 62.50 | 87.69 | 3.62 | 0.0055 |
| Sex, % male | 43.75 | 51.79 | 0.7418 | 0.5360 |
| Tick serology-historical exposure | 3.388 | 0.0381 | ||
| 2 or more | 41.67 | 15.87 | ||
| less than 2 | 58.33 | 84.13 | ||
| Treatment group | 50.00 | 51.31 | 0.9519 | >0.9999 |
| Placebo | 50.00 | 48.69 |
Abbreviations: CanL, canine leishmaniosis. Leish+, showing 2 or more clinical signs of canine leishmaniasis; Leish-, showing less than two clinical signs of canine leishmaniasis or negative for L. infantum via qPCR or DPP®CVL assay; RR, unadjusted relative risk
More exposure to multiple tick-borne diseases leads to worse CanL. Multiple logistic regression with outcome defined as polysymptomatic leishmaniosis; dogs diagnostically positive for Leishmania infantum with three or more specific signs for leishmaniosis
| Variable | Adjusted relative risk | 95% CI | |
|---|---|---|---|
| Age | |||
| ≤ 6 years-old | 8.50 | 2.22–32.51 | 0.0018 |
| Region | |||
| Mid-west | 11.78 | 1.79–77.57 | 0.010 |
| Serology (no. of tick-borne dz) | |||
| 1 | 1.49 | 0.29–7.79 | 0.630 |
| 2 | 1.44 | 0.25–8.40 | 0.690 |
| 3 | 11.65 | 1.22–110.99 | 0.033 |
| 3 | 7.69 | 1.39–43.48 | 0.020 |
| 3 | 8.33 | 1.01–66.67 | 0.049 |
| 2 | 1.04 | 0.27–3.96 | 0.950 |
Notes: Explanatory variables controlled for in the model were age, region, tick serological status (positive vs negative), sex and vaccine status. Only significant variables are shown
Abbreviations: CanL, canine leishmaniosis; CI, confidence interval; dz, disease
Fig. 2Distribution of tick-borne diseases based on CanL clinical status or mortality. Tick-borne disease exposure determined as positive or negative via ELISA. Leishmania spp. determined as diagnostically positive via qPCR and/or DPP® CVL. a Dogs with clinical leishmaniosis determined as dogs with three or more clinical signs of leishmaniosis and diagnostically positive for Leishmania via qPCR and/or DPP® CVL. b All-cause mortality determined as death for any reason
Distribution of co-infections among dogs with clinical leishmaniosis and that died
| Tick-borne exposure | % also CanL | % all-cause mortality |
|---|---|---|
| 41.67 | 20.00 | |
| 50.00 | 26.67 | |
|
| 33.33 | 13.33 |
| 41.67 | 20.00 | |
| 100 | 53.33 |
Notes: Leishmania infantum positive status was determined as any dog that was diagnostically positive via qPCR or is measured by either DPP® CVL assay or PCR-positive. Clinical leishmaniosis was determined as dogs with 2 or more clinical signs for leishmaniosis and a diagnostic positive test results on qPCR and/or DPP® CVL